

# Ros Wade

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6542852/publications.pdf>

Version: 2024-02-01

27  
papers

721  
citations

623574

14  
h-index

552653

26  
g-index

27  
all docs

27  
docs citations

27  
times ranked

1023  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Cost-Effectiveness of Selective Internal Radiation Therapies Compared With Sorafenib for Treating Advanced Unresectable Hepatocellular Carcinoma in the United Kingdom. <i>Value in Health</i> , 2022, 25, 787-795.	0.1	1
2	Characteristics modifying response to biological treatments for psoriasis: considering subgroups in network meta-analysis. <i>British Journal of Dermatology</i> , 2021, 184, 358-359.	1.4	1
3	QUADAS-C: A Tool for Assessing Risk of Bias in Comparative Diagnostic Accuracy Studies. <i>Annals of Internal Medicine</i> , 2021, 174, 1592-1599.	2.0	88
4	Methods for selecting the best evidence to inform a NICE technology appraisal on selective internal radiation therapies for hepatocellular carcinoma. <i>Systematic Reviews</i> , 2020, 9, 184.	2.5	2
5	Patient characteristics as effect modifiers for psoriasis biologic treatment response: an assessment using network meta-analysis subgroups. <i>Systematic Reviews</i> , 2020, 9, 132.	2.5	14
6	Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation. <i>Health Technology Assessment</i> , 2020, 24, 1-264.	1.3	4
7	Hyperhidrosis quality of life measures: review and patient perspective. <i>Journal of Dermatological Treatment</i> , 2019, 30, 303-308.	1.1	19
8	Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2019, 37, 131-139.	1.7	7
9	The Clinical and Cost Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2019, 37, 1081-1091.	1.7	5
10	Interventional management of hyperhidrosis in secondary care: a systematic review. <i>British Journal of Dermatology</i> , 2018, 179, 599-608.	1.4	25
11	A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the Evidence. <i>Pharmacoeconomics</i> , 2017, 35, 203-213.	1.7	6
12	Systematic review of patient preference and adherence to the correct use of graduated compression stockings to prevent deep vein thrombosis in surgical patients. <i>Journal of Advanced Nursing</i> , 2017, 73, 336-348.	1.5	29
13	Interventions for hyperhidrosis in secondary care: a systematic review and value-of-information analysis. <i>Health Technology Assessment</i> , 2017, 21, 1-280.	1.3	10
14	Thigh length versus knee length antiembolism stockings for the prevention of deep vein thrombosis in postoperative surgical patients; a systematic review and network meta-analysis. <i>BMJ Open</i> , 2016, 6, e009456.	0.8	8
15	Apremilast for the Treatment of Moderate to Severe Plaque Psoriasis: A Critique of the Evidence. <i>Pharmacoeconomics</i> , 2016, 34, 587-596.	1.7	3
16	Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence. <i>Pharmacoeconomics</i> , 2015, 33, 1269-1279.	1.7	13
17	The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence. <i>Pharmacoeconomics</i> , 2015, 33, 457-466.	1.7	21
18	Graduated compression stockings for the prevention of deep-vein thrombosis in postoperative surgical patients: a systematic review and economic model with a value of information analysis. <i>Health Technology Assessment</i> , 2015, 19, 1-220.	1.3	26

#	ARTICLE	IF	CITATIONS
19	The EOS 2D/3D X-ray imaging system: A cost-effectiveness analysis quantifying the health benefits from reduced radiation exposure. <i>European Journal of Radiology</i> , 2013, 82, e342-e349.	1.2	49
20	Ruxolitinib for the Treatment of Myelofibrosis: A NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2013, 31, 841-852.	1.7	16
21	Quality assessment of comparative diagnostic accuracy studies: our experience using a modified version of the QUADAS tool. <i>Research Synthesis Methods</i> , 2013, 4, 280-286.	4.2	46
22	A systematic review of the clinical effectiveness of EOS 2D/3D X-ray imaging system. <i>European Spine Journal</i> , 2013, 22, 296-304.	1.0	83
23	Adjunctive colposcopy technologies for examination of the uterine cervix – DySIS, LuViva Advanced Cervical Scan and Niris Imaging System: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2013, 17, i-239.	1.3	20
24	Systematic review and meta-analysis of the value of clinical features to exclude radiographic pneumonia in febrile neutropenic episodes in children and young people. <i>Journal of Paediatrics and Child Health</i> , 2012, 48, 641-648.	0.4	11
25	Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. <i>BMC Medicine</i> , 2012, 10, 6.	2.3	65
26	EOS 2D/3D X-ray imaging system: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2012, 16, 1-188.	1.3	98
27	Systematic review and meta-analysis of the discriminatory performance of risk prediction rules in febrile neutropaenic episodes in children and young people. <i>European Journal of Cancer</i> , 2010, 46, 2950-2964.	1.3	51